EVAX Evaxion
Price Chart
Executive Summary
Evaxion announced a poster presentation at the EHA 2026 Congress detailing preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine. The data supports progression toward clinical testing, with a clinical trial application planned for H2 2026. This is a positive pipeline update but remains early-stage and non-revenue generating.
Actionable Insight
Monitor the EHA 2026 poster presentation on June 13 for any data that could de-risk EVX-04 and attract partnership interest. The clinical trial application in H2 2026 is the next major catalyst.
Key Facts
- EVX-04 is an off-the-shelf therapeutic AML vaccine targeting endogenous retrovirus (ERV) tumor antigens.
- Preclinical data will be presented at EHA 2026 Congress on June 13, 2026.
- Evaxion plans to submit a clinical trial application in the second half of 2026.
- EVX-04 prevented tumor growth in preclinical tumor models.
- AML is the most frequent leukemia, with a median age at diagnosis of 68 years and poor survival rates.
Financial Impact
No financial data disclosed; preclinical stage with no revenue impact.
Risk Factors
- EVX-04 is still preclinical; clinical failure risk is high.
- Evaxion has no approved products and requires additional capital to fund development.
- Competition from other AML therapies could limit commercial potential.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293006 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
9d ago
|
6-K
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $4.02 (−3.60%) |
|
May 12, 2026
9d ago
|
Press Release
| $4.17 $4.09 | ▼ −1.92% | ▼ −2.00% | $4.02 (−3.60%) |
|
May 7, 2026
14d ago
|
6-K
| $4.07 $4.16 | ▲ +2.21% | ▲ +0.71% | $4.02 (−1.23%) |
|
May 4, 2026
17d ago
|
Press Release
| $4.57 $4.23 | ▼ −7.55% | ▼ −10.49% | $4.02 (−12.04%) |
|
Apr 27, 2026
24d ago
|
6-K
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $4.02 (−3.83%) |
|
Apr 27, 2026
24d ago
|
Press Release
| $4.18 $4.57 | ▲ +9.33% | ▲ +8.93% | $4.02 (−3.83%) |
|
Apr 22, 2026
29d ago
|
6-K
| $4.27 $4.27 | · 0.00% | ▼ −0.05% | $4.02 (−5.85%) |
|
Apr 17, 2026
4w ago
|
6-K
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $4.02 (−9.66%) |
|
Apr 17, 2026
4w ago
|
6-K
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $4.02 (−9.66%) |
|
Apr 17, 2026
4w ago
|
Press Release
| $4.45 $4.03 | ▼ −9.44% | ▼ −9.99% | $4.02 (−9.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access